Does splenic preservation treatment (embolization, splenorrhaphy, and partial splenectomy) improve immunologic function and long-term prognosis after splenic injury?
BACKGROUND
: To assess the immunologic alteration and long-term prognosis after splenic injury from preservation treatment (PT) (embolization, splenorrhaphy, partial splencetomy) and to compare with splenectomy (SN).


METHODS
: The long-term prognosis of patients with blunt splenic injury treated at seven tertiary emergency centers in Japan was retrospectively studied. Patients were followed up by telephone interview and written questionnaire. Blood samples and abdominal computer tomography scans were taken from patients who consented, and immunologic indices and the remaining volume of the spleen were measured.


RESULTS
: There was no episode of severe infection requiring hospitalization among the 66 SN patients (760 patient-year) and the 34 PT (213 patient-year) patients. Blood tests from 58 patients (24 SN vs. 34 PT) revealed significant differences in platelet count, Howell-Jolly body positive rate (SN 87% vs. PT 3%), white blood cells, total lymphocyte count, T-cell count, B-cell count, and serum IgG level. There was no significant difference in serum levels of IgM or specific IgG antibodies against 14 types of Streptococcus pneumoniae capsular polysaccharide, C3, C4, high-sensitivity C-reactive protein, and B -cell subset (surface marker immunoglobulins: IgA, IgG, and IgM). Most patients had anti-S. pneumoniae antibody levels less than that of the reference level for multiple serotypes (average 3 in SN and 4 in PT). A computer tomography scan was taken from 33 PT patients; the volume of spleen remaining averaged 130 mL (range, 48-287 mL).


CONCLUSIONS
: PT did not show discernible advantage over SN in immunologic indices including IgM and 14 serotypes of anti-S. pneumoniae antibodies, suggesting prophylactic measures and close follow-up are necessary after PT and SN.
Nakae
Haruhiko
H
Department of Emergency Room Medicine, Kinki University, School of Medicine, Osaka, Japan.
Shimazu
Takeshi
T
Miyauchi
Hiroshi
H
Morozumi
Junya
J
Ohta
Shoichi
S
Yamaguchi
Yoshihiro
Y
Kishikawa
Masanobu
M
Ueyama
Masashi
M
Kitano
Mitsuhide
M
Ikeuchi
Hisashi
H
Yukioka
Tetsuo
T
Sugimoto
Hisashi
H
D000328:Adult; D000917:Antibody Formation / Q000502:physiology; D015331:Cohort Studies; D004621:Embolization, Therapeutic; D005260:Female; D006801:Humans; D007111:Immunity, Cellular / Q000502:physiology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D020127:Recovery of Function; D012189:Retrospective Studies; D013154:Spleen / Q000276:immunology / Q000293:injuries*; D013156:Splenectomy; D014949:Wounds, Nonpenetrating / Q000175:diagnosis / Q000276:immunology* / Q000628:therapy*; D055815:Young Adult